-
Product Insights
NewInnovations in Cortical Stimulators – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Cortical Stimulators - Global Pipeline Summary" provides comprehensive information about the Cortical Stimulators pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Cortical Stimulators report provides key information and data related to: Extensive coverage of the Cortical Stimulators under development Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories,...
-
Product Insights
Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) – Drugs In Development, 2023
Global Markets Direct’s, ‘Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) - Drugs In Development, 2023’, provides an overview of the Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Everolimus in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in Epilepsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Epilepsy Drug Details: Everolimus is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Radiprodil in Tuberous Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Radiprodil in Tuberous Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radiprodil in Tuberous Sclerosis Drug Details: Radiprodil is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Radiprodil in Seizures
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Radiprodil in Seizures report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radiprodil in Seizures Drug Details: Radiprodil is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AV-078 in Tuberous Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AV-078 in Tuberous Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AV-078 in Tuberous Sclerosis Drug Details: AV-078 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TPI-287 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TPI-287 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TPI-287 in Breast Cancer Drug Details: ARC-100 (TPI 287) is under development...
-
Product Insights
Spinal Fusion Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Spinal Fusion Pipeline Market Report Overview Spinal Fusion procedures are mainly performed on the cervical and thoracolumbar regions. Spinal fusion is a surgical procedure that involves joining two vertebrae in the spine to form a single solid bone, with the involvement of certain devices, to relieve pain. Conventional and Minimally Invasive Surgery (MIS) methods are used to perform Spinal Fusion. Conventional methods include all open surgical methods that are used for performing spinal procedures. The Spinal Fusion pipeline market research...
-
Product Insights
Progressive Supranuclear Palsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Progressive Supranuclear Palsy - Drugs In Development, 2023’, provides an overview of the Progressive Supranuclear Palsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,...